Allogene Therapeutics reported cash from operations of -$32.00M and free cash flow of -$32.01M for the quarter ended Jun 2026, up 18.0% year over year. This cash flow statement covers 34 quarters of results from Mar 2018 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Mar2018 | Jun2018 | Sep2018 | Dec2018 | Mar2019 | Jun2019 | Sep2019 | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||||||||||||||||||||||
| Net Income | -78.19M | 0.73M | -79.87M | -76.30M | -81.51M | -93.64M | -99.97M | -76.76M | -56.79M | -75.91M | -64.07M | -66.44M | -65.17M | -57.54M | -59.83M | -50.90M | -41.32M | -39.06M | -42.82M | -42.62M | ||||||||||||||
| Share-based Compensation | 20.86M | 22.04M | 22.32M | 22.89M | 21.15M | 17.25M | 18.77M | 16.59M | 15.35M | 15.23M | 11.92M | 13.56M | 13.39M | 12.87M | 12.18M | 8.69M | 8.65M | 8.13M | 8.27M | 12.44M | ||||||||||||||
| Deferred Taxes | ||||||||||||||||||||||||||||||||||
| Asset Writedowns and Impairment | 10.24M | 5.00M | 10.73M | 2.38M | 0.02M | |||||||||||||||||||||||||||||
| Cash from Operations | -48.88M | -45.44M | -68.24M | -42.53M | -47.66M | -62.10M | -66.64M | -61.86M | -55.53M | -53.71M | -55.90M | -63.59M | -44.12M | -36.70M | -52.93M | -39.03M | -29.69M | -27.60M | -12.91M | -32.00M | ||||||||||||||
| Depreciation, Depletion & Amortization | ||||||||||||||||||||||||||||||||||
| Depreciation & Amortization (CF)Depreciation & Amortization | 3.57M | 3.48M | 3.56M | 3.64M | 3.21M | 3.23M | 3.10M | 3.11M | 3.10M | 3.10M | 2.87M | 2.65M | ||||||||||||||||||||||
| Change in Working Capital | ||||||||||||||||||||||||||||||||||
| Change in Account Payables | 0.19M | -2.04M | -0.51M | 1.42M | 1.01M | 2.94M | 1.06M | -4.29M | -3.97M | -0.30M | -0.12M | 6.81M | -7.23M | 0.03M | -0.34M | -0.42M | -1.07M | 0.60M | 0.66M | 1.03M | ||||||||||||||
| Change in Accured Expenses | 8.89M | -2.77M | -9.05M | 5.71M | 1.95M | 3.14M | 5.69M | -0.08M | -12.72M | 0.29M | -5.69M | -0.98M | 2.53M | 2.88M | -5.22M | 1.74M | 1.09M | -0.12M | -5.10M | 2.28M | ||||||||||||||
| Other Working Capital Changes | 4.91M | -5.35M | -0.60M | -0.43M | -0.43M | -1.06M | -1.26M | -0.10M | -3.08M | -1.56M | -1.21M | -1.64M | -1.69M | -1.78M | -1.83M | -1.93M | -1.85M | -1.89M | -2.20M | -2.04M | ||||||||||||||
| Investing Activities | ||||||||||||||||||||||||||||||||||
| Capital Expenditures | 3.35M | 0.74M | 3.11M | 0.16M | 0.22M | 1.69M | 1.03M | 0.29M | 0.01M | 0.18M | -1.45M | -0.68M | -1.47M | -0.69M | -0.42M | 1.93M | -0.32M | 0.10M | 0.15M | 0.01M | ||||||||||||||
| Change in Acquisitions & Divestments | 161.78M | 82.54M | 68.68M | 117.12M | 74.58M | 99.08M | 143.44M | 152.87M | 165.16M | 136.34M | 103.27M | 117.22M | 109.80M | 102.17M | 56.50M | 53.80M | 61.91M | 61.99M | 72.11M | 36.31M | ||||||||||||||
| Cash from Investing Activities | 13.01M | 29.25M | -22.38M | 54.03M | 24.91M | 49.60M | 112.94M | 17.16M | -34.27M | 67.46M | 22.13M | 74.61M | -75.99M | 54.93M | 6.18M | 43.84M | 11.94M | 33.61M | -29.59M | -147.56M | ||||||||||||||
| Financing Activities | ||||||||||||||||||||||||||||||||||
| Other financing activities | 0.75M | 0.32M | 1.53M | -0.00M | 0.93M | 1.73M | 0.77M | 0.86M | 1.42M | 3.35M | 3.56M | 0.45M | ||||||||||||||||||||||
| Debt Issuance and Repayment | ||||||||||||||||||||||||||||||||||
| Long-Term Debt Issuances | ||||||||||||||||||||||||||||||||||
| Change in Capital Stock | ||||||||||||||||||||||||||||||||||
| Net Shares Issued and Repurchased | ||||||||||||||||||||||||||||||||||
| Net Equity Issued and Repurchased | 3.19M | 105.28M | 10.00M | 1.51M | 2.98M | 7.86M | 20.67M | 167.20M | ||||||||||||||||||||||||||
| Misc. | ||||||||||||||||||||||||||||||||||
| Cash from Financing Activities | 2.38M | 0.32M | 1.81M | 0.02M | 1.07M | 0.05M | 1.73M | 89.52M | 4.29M | 0.15M | 1.65M | 108.60M | 0.68M | 5.74M | 13.99M | 5.07M | 3.24M | 7.86M | 21.12M | 187.87M | ||||||||||||||
| Change in Cash | -33.48M | -15.86M | -88.80M | 11.53M | -21.68M | -12.45M | 48.03M | 44.83M | -85.51M | 13.91M | -32.12M | 119.63M | -119.43M | 23.98M | -32.76M | 9.88M | -14.52M | 13.87M | -21.38M | 8.32M | ||||||||||||||
| Free Cash Flow | -52.23M | -46.17M | -71.35M | -42.69M | -47.88M | -63.79M | -67.67M | -62.15M | -55.54M | -53.89M | -54.45M | -62.91M | -42.65M | -36.01M | -52.50M | -40.96M | -29.37M | -27.70M | -13.06M | -32.01M | ||||||||||||||
| Net Cash Flow | -33.48M | -15.86M | -88.80M | 11.53M | -21.68M | -12.45M | 48.03M | 44.83M | -85.51M | 13.91M | -32.12M | 119.63M | -119.43M | 23.98M | -32.76M | 9.88M | -14.52M | 13.87M | -21.38M | 8.32M |